Results of a Phase 2b Trial With GB001, a Prostaglandin D Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma.

Background: Prostaglandin D receptor 2 (DP) antagonists inhibit prostaglandin D-induced effects, including recruitment and activation of cells driving asthma pathogenesis. However, challenges identifying target population and end points persist.

Research Question: What is the effect of the DP antagonist GB001 on asthma worsening in patients with moderate to severe eosinophilic asthma?

Study Design And Methods: In this phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multicenter study, GB001 or placebo was added to standard-of-care treatment in patients with moderate to severe asthma with a blood eosinophil count ≥ 250 cells/μL.

Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis.

Background: Epithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with protective roles at the epithelial layer of the inflamed gut.

Aims: To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of GB004 in patients with active UC.

Instantaneous interaction of mucin with pectin- and carrageenan-coated nanoemulsions.

The efficiency of drug delivery and sensory perception is intertwined with mucoadhesive systems. The physiochemical characteristics of mucus induce flocculation of emulsion droplets, which could significantly influence their sensory perception. In this study, we investigated the interactions between pectin- and carrageenan-coated nanoemulsions with mucin.

A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.

Background: GB001 is an oral antagonist of the prostaglandin D2 receptor that may inhibit recruitment and activation of airway eosinophils, reducing airway inflammation.

Objective: To assess GB001 safety, efficacy and pharmacokinetics from a Phase 2 study and explore the association between type 2 biomarkers (fractional exhaled nitric oxide and blood eosinophils) and asthma control markers following GB001 administration.

Methods: A randomized, placebo-controlled, double-blind study evaluating 36 patients with mild-to-moderate atopic asthma.